Navigation Links
Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
Date:12/19/2007

ing patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease and other areas of unmet medical need.

This press release contains forward-looking statements, including Genzyme's belief that a single-injection regimen of Synvisc will simplify pain management, provide additional patient convenience, reduce costs and expand the viscosupplementation market, and Genzyme's plans to pursue marketing approvals in additional jurisdictions. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, among others, the extent to which the government and private insurers recognize the benefits of Synvisc-One and maintain or otherwise implement reimbursement policies that reflect these benefits, whether doctor's recognize the benefits of Synvisc-One and adopt it as a preferred treatment option and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

Genzyme(R) and Synvisc(R) are registered trademarks and Synvisc-One(TM) is a trademark of Genzyme Corporation. All rights reserved.

Genzyme's press
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/10/2014)... Women in the West African ... additional family planning option. Sayana® Press has the ... levels of the health system and in communities ... used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the BD ... first of four African countries expected to begin ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Wis. - Leaders of Milwaukee, Racine, and Waukesha ... support to the expansion of the Center for ... the three counties is intended to increase the number ... in southeastern Wisconsin, in order to keep area innovations ...
... Cash, Clout, Connections, Commitment. These are the 4 C's that ... private-public board. I've always felt that each "C" was equally ... as the folks with thick wallets, and so forth. Until ... hour board retreat for an organization I love. It was ...
... Madison, Wis. - When Berbee Information Networks ... the company with two guiding principles: high quality customer service ... channeled these philosophies to create one of the largest and ... refuses to stay still in its market space, regularly training ...
Cached Biology Technology:Southeastern Wisconsin Technology Collaboration 2Southeastern Wisconsin Technology Collaboration 3Southeastern Wisconsin Technology Collaboration 4Are boards broken? 2Berbee puts people first to deliver high-quality technology 2Berbee puts people first to deliver high-quality technology 3Berbee puts people first to deliver high-quality technology 4
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... June 27, 2014  The American Academy of ... of Standards and Technology (NIST) and the Department ... research and forensic science expert members to the ... an element of the NIST,s Organization of Scientific ... the first appointments made to the new FSSB ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... 22, 2012 Intersil Corporation (NASDAQ Global Select: ... die offerings through authorized distributor Micross Components. ... partner, Micross will play an instrumental role in ... in specialty applications," said Tony Ochoa, Marketing Director, ...
... study carried out at the University of Leicester,s School ... disagreeable are more likely to prefer aggressive dogs, confirming ... their owners. Researchers found that low Agreeableness was ... seen as more aggressive, such as bull terriers or ...
... 2012) Researchers from the University of Minnesota and Washington ... grain products in the United States may have an impact ... published online today in the journal Pediatrics , shows ... to increase, and also finds a notable decrease in two ...
Cached Biology News:Intersil Expands Precision Analog IC Offerings with Micross Components 2University of Leicester study finds low agreeableness linked to a preference for aggressive dogs 2Folic acid food enrichment potentially protective against childhood cancers 2
... identification through targeting resequencing. This ... assay validation/optimization, high throughput PCR setup ... samples and sequence alignment and analysis.,Agencourts ... and highly accurate identification of SNP ...
... Gene/cDNA or Isolated Sequence) siRNA Test System ... for evaluation of a potential of any ... target for RNA interference (RNAi). Current computer-based ... leaving the probability of selected sequence to ...
... a is a bovine protein-free alternative to ... an aqueous solution that contains non-toxic chemicals ... pH 6.6 - 7.2. This product ... 0.02% bromonitrodioxane as a preservative. StabilGuard ...
... antigen, Monoclonal Antibody, Unconjugated ... at an assay dependent dilution. IF: ... WB: Use at an assay dependent ... Not tested in other applications. ...
Biology Products: